WINTON GROUP Ltd Makes New $1.42 Million Investment in Qiagen N.V. $QGEN

WINTON GROUP Ltd purchased a new stake in Qiagen N.V. (NYSE:QGEN) in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 36,400 shares of the company’s stock, valued at approximately $1,423,000.

A number of other large investors also recently made changes to their positions in QGEN. Danske Bank A S acquired a new stake in shares of Qiagen during the third quarter worth $36,000. Manchester Capital Management LLC acquired a new position in Qiagen in the fourth quarter valued at $42,000. Hilltop National Bank purchased a new position in Qiagen during the second quarter worth about $50,000. Global Retirement Partners LLC lifted its position in Qiagen by 279.9% during the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after buying an additional 851 shares during the period. Finally, Integrated Wealth Concepts LLC purchased a new position in Qiagen during the second quarter worth about $59,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

Shares of Qiagen stock opened at $42.39 on Friday. The business’s fifty day moving average price is $42.20 and its 200 day moving average price is $40.18. Qiagen N.V. has a twelve month low of $32.53 and a twelve month high of $57.81. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $8.74 billion, a P/E ratio of 21.72, a PEG ratio of 4.23 and a beta of 0.63.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. The company had revenue of $535.04 million during the quarter, compared to analyst estimates of $527.50 million. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The firm’s revenue was up .2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, research analysts anticipate that Qiagen N.V. will post 2.43 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on QGEN. Citigroup restated a “neutral” rating and issued a $45.00 price target (up from $38.00) on shares of Qiagen in a report on Monday, August 10th. Weiss Ratings upgraded shares of Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday. Kepler Capital Markets set a $38.60 target price on shares of Qiagen and gave the stock a “hold” rating in a research report on Thursday, June 25th. UBS Group initiated coverage on shares of Qiagen in a report on Wednesday. They issued a “neutral” rating and a $47.00 target price for the company. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price target on shares of Qiagen in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Qiagen currently has a consensus rating of “Hold” and an average price target of $43.51.

Qiagen Profile

QIAGEN N.V. is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.

Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing.